Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

vadimezan

A fused tricyclic analogue of flavone acetic acid with potential antineoplastic activity. Vadimezan induces the cytokines tumor necrosis alpha (TNF-alpha), serotonin and nitric oxide, resulting in hemorrhagic necrosis and a decrease in angiogenesis. This agent also stimulates the anti-tumor activity of tumor-associated macrophages.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	Dimethyloxoxanthene Acetic Acid
Abbreviation:	5,6-MexXAA DMXAA
Code name:	AS1404 ASA404
Chemical structure:	5,6-Dimethylxanthenone-4-Acetic Acid

vadimezan

Search NCI's Drug Dictionary